Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00314288 · ClinicalTrials.gov registry record · Phase 2
Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia
A Phase 2 study, sponsored by EMD Serono.
- Completed
- Registry status
- Phase 2
- Development phase
- 360
- Enrollment target
NCT00314288: Completed Phase 2 study, sponsored by EMD Serono.
NCT00314288 is a Phase 2 study that has completed, run by EMD Serono. The registered enrollment target is 360 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (171% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00314288, a Phase 2 study, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 360 participants
- Enrollment target
Study Summary
The primary purpose of the study is to investigate the anti-dyskinetic effect of several doses of sarizotan in Parkinson patients in order to generate information on the dose-response relationship (dose-finding).
Interventions
- DRUG Sarizotan HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2002-07 |
| Est. Completion | 2003-07 |
| Phase | Phase 2 |
What the finished NCT00314288 record still lists
NCT00314288 is an interventional study that assigns participants to a tested intervention. The registered 360 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (171% higher).
The record links to 0 conditions, and to 1 intervention - of which Sarizotan HCl is the first listed.
NCT00314288 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00314288 about?
NCT00314288 is a clinical study titled "Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia". The primary purpose of the study is to investigate the anti-dyskinetic effect of several doses of sarizotan in Parkinson patients in order to generate information on the dose-response relationship (dose-finding).
What is the current status of trial NCT00314288?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 360 participants. The study started on 2002-07. Estimated completion is 2003-07.
What interventions are being tested in trial NCT00314288?
The interventions under investigation include: Sarizotan HCl (DRUG).
Who is sponsoring clinical trial NCT00314288?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00314288's enrollment target sits among peer trials
360 123rd of 2000 higher than 1,874 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747836 · 360 participants
Ultrasound Analysis of Human Carpal Tunnel System
- NCT04089046 · 360 participants · NA
Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)
- NCT04130503 · 360 participants · NA
The Recovery in Stroke Using PAP Study
- NCT04160000 · 360 participants · Phase 4
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia